Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An announcement from GlaxoSmithKline ( (GB:GSK) ) is now available.
GSK plc has continued its share buyback programme, repurchasing 345,000 ordinary shares on 1 April 2026 through BNP Paribas at a volume-weighted average price of 2,106.14 pence, with the shares to be held in treasury. Since mid-February, the company has bought back more than 16.5 million shares, lifting treasury holdings to about 256.5 million shares and leaving 4.06 billion shares in issue, which adjusts the total voting rights and may influence shareholder ownership calculations under UK disclosure rules.
The most recent analyst rating on (GB:GSK) stock is a Sell with a £19.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
Spark’s Take on GSK Stock
According to Spark, TipRanks’ AI Analyst, GSK is a Neutral.
The score is driven primarily by strong profitability and improving recent fundamentals, supported by constructive 2026 guidance and pipeline momentum. Valuation is reasonable with a modest yield, while the main constraint is technical overbought risk and ongoing balance-sheet/earnings-consistency considerations.
To see Spark’s full report on GSK stock, click here.
More about GlaxoSmithKline
GSK plc is a global biopharmaceutical company focused on the research, development and commercialization of vaccines, specialty medicines and general medicines. The group operates across major therapeutic areas, supplying prescription treatments and vaccines to international markets, and is a constituent of the UK’s blue-chip equity indices.
Average Trading Volume: 9,512,363
Technical Sentiment Signal: Buy
Current Market Cap: £82.51B
See more insights into GSK stock on TipRanks’ Stock Analysis page.